Literature DB >> 2159348

Continuous phosphorylation of both the 47 and the 49 kDa proteins occurs during superoxide production by neutrophils.

P G Heyworth1, J A Badwey.   

Abstract

Neutrophils stimulated with 4 beta-phorbol 12-myristate 13-acetate release large quantities of superoxide (O2-) and exhibit an intense phosphorylation of two proteins with molecular masses of approx. 47 and 49 kDa. Treatment of unstimulated cells with antagonists of protein kinase C (e.g., staurosporine; 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7)) is known to inhibit both of these phenomena upon stimulation. These antagonists of PKC also cause a rapid cessation of O2- release when added to cells that are already stimulated. In this paper, we report that the addition of staurosporine or H-7 to stimulated neutrophils resulted in a rapid loss of 32P from both the 47 and the 49 kDa phosphoprotein bands, as detected by autoradiography. This suggests that these two proteins may be regulated by a continual cycle of phosphorylation and dephosphorylation in the stimulated cell, with the phosphorylation reactions predominating, or undergo a rapid degradation subsequent to phosphorylation. Either explanation is consistent with the view that protein kinase C activity is necessary to both initiate and maintain O2- production in neutrophils stimulated with tumor promoters.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159348     DOI: 10.1016/0167-4889(90)90225-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Multiple mechanisms of NADPH oxidase inhibition by type A and type B Francisella tularensis.

Authors:  Ramona L McCaffrey; Justin T Schwartz; Stephen R Lindemann; Jessica G Moreland; Blake W Buchan; Bradley D Jones; Lee-Ann H Allen
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

2.  Another biological effect of tosylphenylalanylchloromethane (TPCK): it prevents p47phox phosphorylation and translocation upon neutrophil stimulation.

Authors:  Maggaly Gillibert; Zakia Dehry; Micheline Terrier; Jamel El Benna; Florence Lederer
Journal:  Biochem J       Date:  2005-03-15       Impact factor: 3.857

Review 3.  Nox enzymes in immune cells.

Authors:  William M Nauseef
Journal:  Semin Immunopathol       Date:  2008-05-01       Impact factor: 9.623

4.  Human neutrophil NADPH-oxidase activity is inhibited by lazaroids.

Authors:  A J Theron; R Anderson
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

5.  Sustained activation of proton channels and NADPH oxidase in human eosinophils and murine granulocytes requires PKC but not cPLA2 alpha activity.

Authors:  Deri Morgan; Vladimir V Cherny; Alison Finnegan; James Bollinger; Michael H Gelb; Thomas E DeCoursey
Journal:  J Physiol       Date:  2006-12-21       Impact factor: 5.182

Review 6.  Multifaceted effects of Francisella tularensis on human neutrophil function and lifespan.

Authors:  Lauren C Kinkead; Lee-Ann H Allen
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

Review 7.  The NADPH oxidase complex of phagocytic leukocytes: a biochemical and cytochemical view.

Authors:  J M Robinson; J A Badwey
Journal:  Histochem Cell Biol       Date:  1995-03       Impact factor: 4.304

8.  Relationship between phosphorylation and translocation to the plasma membrane of p47phox and p67phox and activation of the NADPH oxidase in normal and Ca(2+)-depleted human neutrophils.

Authors:  S Dusi; V Della Bianca; M Grzeskowiak; F Rossi
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

9.  C-reactive protein (CRP) peptides inactivate enolase in human neutrophils leading to depletion of intracellular ATP and inhibition of superoxide generation.

Authors:  E G Shephard; R Anderson; O Rosen; M Fridkin
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

10.  Activation of NADPH oxidase of human neutrophils involves the phosphorylation and the translocation of cytosolic p67phox.

Authors:  S Dusi; F Rossi
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.